Repligen other research news

The company announced it obtained exclusive worldwide rights to human B7-2, a new immune stimulator whose discovery was published in Science. The costimulator was found in collaborative research between RGEN and the Dana-Farber Cancer Institute, and a patent on the agent and related molecules has been filed jointly.

Prior to the discovery, a costimulatory factor called B7 had been proposed to help activate T cells, along with antibody presentation. But mice lacking B7 show only a partial defect in immune response, as reported in Science. The new protein, as detailed in an accompanying Science report, appears to be present earlier than B7. ...